Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Total Liabilities (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Total Liabilities for 3 consecutive years, with $289.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 276.25% to $289.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $289.1 million, a 276.25% increase, with the full-year FY2025 number at $289.1 million, up 276.25% from a year prior.
  • Total Liabilities was $289.1 million for Q4 2025 at Nuvation Bio, up from $275.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $289.1 million in Q4 2025 to a low of $16.0 million in Q1 2023.
  • A 3-year average of $100.7 million and a median of $65.8 million in 2024 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 369.61% in 2024; the steepest drop was 19.37% in 2024.
  • Nuvation Bio's Total Liabilities stood at $16.4 million in 2023, then soared by 369.61% to $76.8 million in 2024, then skyrocketed by 276.25% to $289.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Total Liabilities are $289.1 million (Q4 2025), $275.7 million (Q3 2025), and $274.3 million (Q2 2025).